Delivery Order SPE2DB24D2105-SPE2DB25FAPZQ
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $15,204.28 to AmerisourceBergen Drug Corp on August 20, 2025, for the supply of Zepbound (semaglutide) 7.5 mg/0.5 mL pen injections. This is a firm fixed-price, competitively awarded contract with no set-aside designation and a completion date of August 21, 2025. The pharmaceutical product will be delivered to the company's corporate office location in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its primary...
- The Defense Logistics Agency awarded a $19,343.26 delivery order to AmerisourceBergen Drug Corp on July 24, 2025, for the supply of Zepbound (semaglutide) 10 mg/0.5 mL pens. This competitively awarded, firm fixed-price contract is classified as a non-set-aside procurement and requires completion by July 25, 2025. The product will be delivered to AmerisourceBergen's facility in Conshohocken, Pennsylvania, where the company maintains its corporate headquarters. This delivery order is issued...
- The Defense Logistics Agency awarded a $1,298.76 firm fixed-price delivery order to AmerisourceBergen Drug Corp for Zepbound (semaglutide) 5 mg/0.5 mL pens on July 24, 2025, with an ultimate completion date of July 25, 2025. This is a non-set-aside contract, indicating open competition. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor serving federal medical procurement needs, particularly for military and veteran healthcare systems. The...
- The Defense Logistics Agency awarded a $3,266.90 delivery order to AmerisourceBergen Drug Corp on July 22, 2025, for the supply of Zepbound (semaglutide) 2.5 mg/0.5 mL pen injections. The contract, which is not set-aside and was competitively awarded, has a performance location in Conshohocken, Pennsylvania, with an ultimate completion date of July 23, 2025. This delivery order operates under a firm fixed price structure and represents a child contract issued against AmerisourceBergen's larger...
- The Defense Logistics Agency awarded a $10,285.92 delivery order to AmerisourceBergen Drug Corp on August 14, 2025, for the supply of Zepbound (semaglutide) 5 mg/0.5 mL pen injectors. This is a firm fixed price, competitively awarded contract with a completion date of August 15, 2025, and performance to be executed at the contractor's Conshohocken, Pennsylvania facility. The delivery order represents a child contract issued under AmerisourceBergen's broader relationship with the Defense...
- The Defense Logistics Agency awarded a delivery order valued at $2,015.96 to AmerisourceBergen Drug Corp for Zepbound 5 mg/0.5 ml pen (semaglutide injection) on July 18, 2025, with an ultimate completion date of July 21, 2025. This is a firm fixed-price delivery order with no set-aside designation, awarded through open competition. The pharmaceutical product will be delivered to the place of performance in Conshohocken, Pennsylvania, where AmerisourceBergen Drug Corp maintains its corporate...
- The Defense Logistics Agency awarded a $13,067.60 delivery order to AmerisourceBergen Drug Corp on August 7, 2025, for the supply of Zepbound (semaglutide) 10 mg/0.5 mL pens under a firm fixed price contract. The order is scheduled for completion by August 8, 2025, with performance to be fulfilled at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This award was competitively awarded with no set-aside designation and represents a relatively small-value transaction...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $50,732.31 to AmerisourceBergen Drug Corp for the supply of Zepbound (semaglutide) 5 mg/0.5 mL pen injections. This non-competitive, firm fixed-price delivery order was awarded on July 21, 2025, with an ultimate completion date of July 22, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order represents a child contract under AmerisourceBergen's larger...
- The Defense Logistics Agency awarded a delivery order valued at $7,116.86 to AmerisourceBergen Drug Corp for Zepbound (semaglutide) 7.5 mg/0.5 ml pens on July 29, 2025, with an ultimate completion date of July 30, 2025. This competitively awarded, firm fixed-price delivery order was placed under AmerisourceBergen's existing Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999.99 billion prime vehicle running through December 2026 that serves as a comprehensive global...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 31, 2025, for the supply of Zepbound (semaglutide) 7.5 mg/0.5 mL pen injections, with a ceiling value of $1,525.20. This firm fixed-price delivery order is scheduled for completion by August 1, 2025, and will be performed at AmerisourceBergen's facility in Conshohocken, Pennsylvania. The award represents a non-set-aside competitive procurement under the company's existing Indefinite Delivery Contract...
- SPE2DB24D2105Indefinite Delivery Contract
- SPE2DB24D2105-SPE2DB25FAPZQDelivery Order
The Defense Logistics Agency awarded a delivery order valued at $11,285.76 to AmerisourceBergen Drug Corp on July 30, 2025, for the supply of Zepbound (semaglutide) 2.5 mg/0.5 mL pen injectors. This is a firm fixed-price, competitively awarded contract with no set-aside designation and a completion date of July 31, 2025. The product will be delivered to AmerisourceBergen's facility in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a comprehensive pharmaceutical supply vehicle valued at $999,999,999.00 and extending through December 2026, which enables the contractor to supply a broad range of medications, vaccines, and medical supplies to support military healthcare programs globally. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor serving as a critical vendor for federal medical procurement. The company demonstrates extensive capability in fulfilling diverse pharmaceutical supply needs through its demonstrated track record of competitively awarded contracts with the DLA Medical Supply Chain, which includes delivery of specialty medications, brand-name and generic drugs, and medical devices across multiple therapeutic areas. This contract supports the Defense Health Agency and other federal healthcare systems' pharmaceutical requirements.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $11.3k | 7/30/25 |